News headlines about Arbutus Biopharma (NASDAQ:ABUS) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arbutus Biopharma earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 43.5920815298475 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Arbutus Biopharma Corporation (ABUS) stock RSI moves to 37.69 – Nasdaq Chronicle (nasdaqchronicle.com)
- Wedbush Downgrades Arbutus Biopharma (ABUS) to Neutral Citing limited Upside in 2018 – StreetInsider.com (streetinsider.com)
- Wedbush softens view on Arbutus on extended timeline for HBV candidates (seekingalpha.com)
- Wedbush Projects Limited Upside For Arbutus Shares This Year, Moves To Sidelines (finance.yahoo.com)
- Arbutus Biopharma (ABUS) Earns Buy Rating from Analysts at Chardan Capital (americanbankingnews.com)
ABUS has been the topic of a number of recent analyst reports. BidaskClub cut Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd. B. Riley initiated coverage on Arbutus Biopharma in a research note on Friday, January 5th. They set a “buy” rating and a $10.00 target price on the stock. ValuEngine cut Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 15th. Wedbush cut Arbutus Biopharma from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $9.00 to $6.00 in a research note on Monday. Finally, Zacks Investment Research cut Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. Arbutus Biopharma presently has an average rating of “Hold” and a consensus price target of $12.38.
Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.51). Arbutus Biopharma had a negative net margin of 796.23% and a negative return on equity of 55.28%. The firm had revenue of $2.50 million during the quarter, compared to the consensus estimate of $0.70 million. equities analysts anticipate that Arbutus Biopharma will post -1.67 earnings per share for the current fiscal year.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.